Koate-dvi is indicated for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii. koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia. koate-dvi contains naturally occurring von willebrand factor, which is co-purified as part of the manufacturing process.koate-dvi is a human plasma-derived factor viii replacement therapy that is indicated to treat patients with hemophilia a for over 10 years. koate-dvi is proven to rapidly increase levels of factor viii and to stop bleeding episodes.1 koate-dvi has a low risk for side effects, is manufactured with dedicated steps to inactivate or remove viruses.